Patient characteristics and outcome variables at baseline in platelet-rich plasma (PRP) group and placebo group
| Platelet-rich plasma group (n=27) | Placebo group (n=27) | |
|---|---|---|
| Mean (SD) age (years) | 49 (8.1) | 50 (9.4) |
| Gender | ||
| Male | 13 (48%) | 13 (48%) |
| Female | 14 (52%) | 14 (52%) |
| Body mass index (kg/m2, mean (SD)) | 26.8 (3.9) | 26.2 (3.5) |
| Duration of symptoms (weeks, median (IQR)) | 36 (24–78) | 26 (16–104) |
| Active in sports | 22 (81%) | 24 (89%) |
| Ankle Activity Score (mean (SD)) | 5.7 (1.8) | 5.5 (1.6) |
| Echo-type I (mean (SD)) | 50.5 (8.5) | 46.5 (7.1) |
| Echo-type II (mean (SD)) | 26.4 (4.6) | 25.6 (5.7) |
| Echo-type III (mean (SD)) | 13.0 (5.7) | 15.7 (5.2) |
| Echo-type IV (mean (SD)) | 10.1 (5.4) | 12.1 (5.6) |
| Echo-type I+II (mean (SD)) | 76.9 (10.8) | 72.1 (10.5) |
| Maximum tendon thickness (mm, mean (SD)) | 9.83 (1.78) | 9.84 (3.05) |
| Neovascularisation score (mean (SD)) | 2.26 (1.16) | 2.15 (1.35) |
There were no significant differences at baseline between both treatment groups